Eko Secures $65M Series C Financing

The Series C round was led by Highland Capital Partners and Questa Capital, with participation from Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures, and other new and existing investors. The new funding will be used to expand in-clinic use of the company's platform of telehealth and AI algorithms for disease screening, and to launch a monitoring program for cardiopulmonary patients at home.

This funding comes on the heels of collaborations the company announced this year with AstraZeneca and 3M, as well as the achievement of product milestones including FDA clearance of its AI suite and the launch of its telehealth platform.

Eko, a cardiopulmonary digital health company, is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, in-person and through telehealth. The company is headquartered in Oakland, California with investments from Highland Capital Partners, Questa Capital, Artis Ventures, NTTVC, DigiTx Partners, Mayo Clinic, Sutter Health, and others.